Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease.

Doyon A, Fischer DC, Bayazit AK, Canpolat N, Duzova A, Sözeri B, Bacchetta J, Balat A, Büscher A, Candan C, Cakar N, Donmez O, Dusek J, Heckel M, Klaus G, Mir S, Özcelik G, Sever L, Shroff R, Vidal E, Wühl E, Gondan M, Melk A, Querfeld U, Haffner D, Schaefer F; 4C Study Consortium.

PLoS One. 2015 Feb 6;10(2):e0113482. doi: 10.1371/journal.pone.0113482. eCollection 2015.

2.

Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase.

Fischer DC, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G, Haffner D.

Ann Clin Biochem. 2012 Nov;49(Pt 6):546-53. doi: 10.1258/acb.2012.011274. Epub 2012 Sep 14.

PMID:
22984195
3.

Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.

Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M.

J Clin Endocrinol Metab. 2014 Nov;99(11):4315-20. doi: 10.1210/jc.2014-2372. Epub 2014 Aug 5.

PMID:
25093620
4.

Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity.

Grethen E, Hill KM, Jones R, Cacucci BM, Gupta CE, Acton A, Considine RV, Peacock M.

J Clin Endocrinol Metab. 2012 May;97(5):1655-62. doi: 10.1210/jc.2011-2280. Epub 2012 Feb 22.

5.

Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.

Malluche HH, Davenport DL, Cantor T, Monier-Faugere MC.

Clin J Am Soc Nephrol. 2014 Jul;9(7):1254-62. doi: 10.2215/CJN.09470913. Epub 2014 Jun 19.

6.

Evaluation of the activity of tartrate-resistant acid phosphatase isoform 5b in normal Chinese children--a novel marker for bone growth.

Chen CJ, Chao TY, Janckila AJ, Cheng SN, Ku CH, Chu DM.

J Pediatr Endocrinol Metab. 2005 Jan;18(1):55-62.

PMID:
15679069
7.

Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women.

Costa AG, Walker MD, Zhang CA, Cremers S, Dworakowski E, McMahon DJ, Liu G, Bilezikian JP.

J Clin Endocrinol Metab. 2013 Dec;98(12):4736-43. doi: 10.1210/jc.2013-2106. Epub 2013 Sep 13.

8.

[Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].

Milovanova LY, Milovanov YS, Kudryavtseva DV, Markina MM, Milovanova SY, Kozlovskaya LV, Lebedeva MV, Beketov VD, Moiseev SV, Mukhin NA, Fomin VV, Svistunov AA.

Ter Arkh. 2015;87(6):10-16. doi: 10.17116/terarkh201587610-16. Russian.

PMID:
26281189
9.

Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.

Lima F, Mawad H, El-Husseini AA, Davenport DL, Malluche HH.

Clin Nephrol. 2019 Apr;91(4):222-230. doi: 10.5414/CN109650.

PMID:
30862350
10.

The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.

Yamada S, Tsuruya K, Yoshida H, Taniguchi M, Haruyama N, Tanaka S, Eriguchi M, Nakano T, Kitazono T.

Clin Endocrinol (Oxf). 2013 Jun;78(6):844-51. doi: 10.1111/cen.12070. Epub 2013 Apr 6.

PMID:
23078546
11.

Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years.

Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Högler W.

J Clin Endocrinol Metab. 2007 Feb;92(2):443-9. Epub 2006 Nov 14.

PMID:
17105843
12.

Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.

Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y.

Clin Endocrinol (Oxf). 2008 Aug;69(2):189-96. doi: 10.1111/j.1365-2265.2008.03187.x. Epub 2008 Jan 23.

PMID:
18221403
13.

Effects of parathyroidectomy on blood bone markers and heart rate variability in patients with stage 5 chronic kidney disease.

Chen H, Cui Y, Xing C, Purrunsing Y, Zha X, Shen C, Zeng M, Yang G, Yu X, Zhang L, Jiang Y, Shen Z, Ma H, Yin C, Li Y, Wang N.

Int Urol Nephrol. 2018 Dec;50(12):2279-2288. doi: 10.1007/s11255-018-1995-6. Epub 2018 Oct 25.

PMID:
30361964
14.

Increase in circulating sclerostin at the early stage of menopausal transition in Japanese women.

Matsui S, Yasui T, Kasai K, Keyama K, Kato T, Uemura H, Kuwahara A, Matsuzaki T, Irahara M.

Maturitas. 2016 Jan;83:72-7. doi: 10.1016/j.maturitas.2015.10.001. Epub 2015 Oct 14.

PMID:
26508082
15.

Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism.

Lu KC, Ma WY, Yu JC, Wu CC, Chu P.

Clin Endocrinol (Oxf). 2012 May;76(5):634-42. doi: 10.1111/j.1365-2265.2011.04265.x.

PMID:
22007930
16.

Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.

Bielesz BO, Hecking M, Plischke M, Cejka D, Kieweg H, Haas M, Marculescu R, Hörl WH, Bieglmayer C, Sunder-Plassmann G.

Clin Biochem. 2014 Sep;47(13-14):1316-9. doi: 10.1016/j.clinbiochem.2014.06.009. Epub 2014 Jun 21.

PMID:
24956265
17.

Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.

Okuno S, Ishimura E, Tsuboniwa N, Norimine K, Yamakawa K, Yamakawa T, Shoji S, Mori K, Nishizawa Y, Inaba M.

Osteoporos Int. 2013 Feb;24(2):605-12. doi: 10.1007/s00198-012-2003-0. Epub 2012 May 12.

PMID:
22581293
18.

Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease.

Siomou E, Challa A, Printza N, Giapros V, Petropoulou F, Mitsioni A, Papachristou F, Stefanidis CJ.

Pediatr Nephrol. 2011 Jul;26(7):1105-14. doi: 10.1007/s00467-011-1870-5. Epub 2011 Apr 9.

PMID:
21479768
19.
20.

Effect of Aerobic Exercise on Markers of Bone Metabolism of Overweight and Obese Patients With Chronic Kidney Disease.

Gomes TS, Aoike DT, Baria F, Graciolli FG, Moyses RMA, Cuppari L.

J Ren Nutr. 2017 Sep;27(5):364-371. doi: 10.1053/j.jrn.2017.04.009. Epub 2017 Jun 9.

PMID:
28606422

Supplemental Content

Support Center